MarketCapExport financials
Oxford Immunotec Global PLC (OXFD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramOxford Immunotec Global PLC Income Statement 2020-2011 | OXFD
Brief overview of income trends at Oxford Immunotec Global PLC
The conclusions below are based on five years of reported results. Revenue reported by Oxford Immunotec Global PLC was 49.5 million dollars at the beginning of the period and 73.7 million dollars at the end. The total change was +48.9%, with a CAGR of approximately 8.3%. Sales increased steadily, although without strong acceleration.
At the gross-profit level, the result moved from 25.5 million dollars to 54.4 million dollars, a change of +113.5%. Gross margin moved from 51.5% to 73.8%. The business retained more gross profit from each unit of revenue.
EBITDA was −$20.1 million at the beginning and −$3.3 million at the end of the period (+83.8%). EBITDA expanded faster than the top line. Comparing the endpoints gives EBITDA margins of −40.6% and −4.4%. The business generated more EBITDA from each unit of revenue.
Across the five years, the net result shifted from −22.2 million dollars to −1.8 million dollars. The loss reduction is constructive, but the recovery is incomplete.
Market capitalization changed from 204 million dollars to 421 million dollars (+106.6%). Higher capitalization indicates improving investor confidence.
Conclusion
The figures do not all move in the same direction. Key strengths include a stronger final result, revenue expansion and positive operating leverage. The most visible risks are a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Oxford Immunotec Global PLC
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 421 M | 369 M | 279 M | 295 M | 253 M | 204 M | 78.8 M | - | - |
Shares |
- | 26.6 M | 26 M | 23.8 M | 22.4 M | 21.8 M | 17.3 M | 3.83 M | - | - |
Net Income |
- | -1.81 M | 121 M | -32.9 M | -22.3 M | -24.5 M | -22.2 M | -8.66 M | -14.9 M | -13.1 M |
Revenue |
- | 73.7 M | 59.8 M | 103 M | 86.1 M | 62.8 M | 49.5 M | 38.8 M | 20.7 M | 12.6 M |
EBITDA |
- | -3.26 M | -16 M | -24.5 M | -22.3 M | -22 M | -20.1 M | -6.25 M | -12.1 M | -12.7 M |
Operating Expenses |
- | 59.4 M | 60.6 M | 85.1 M | 72 M | 57.4 M | 47.4 M | 27.5 M | 21.2 M | 17.5 M |
General and Administrative Expenses |
- | 22.3 M | 26 M | 30.4 M | 23.2 M | 16 M | 14.8 M | 12.1 M | 8.07 M | 5.23 M |
Annual performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Oxford Immunotec Global PLC (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
$ 1.71 | -0.51 % | $ 4.98 M |  USA |
 |
Myriad Genetics
MYGN
|
$ 5.57 | 0.54 % | $ 516 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.14 | 9.18 % | $ 642 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | 1.52 % | $ 133 M | USA |
 |
Agilent Technologies
A
|
$ 177.75 | 2.74 % | $ 50.5 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 344.87 | 9.31 % | $ 17.1 B | USA |
 |
Biodesix
BDSX
|
$ 23.93 | 0.25 % | $ 181 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.51 | 6.71 % | $ 142 M |  China |
 |
Bioventus
BVS
|
$ 14.24 | 2.08 % | $ 949 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
$ 70.74 | 2.23 % | $ 3.77 B | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.64 | -0.82 % | $ 851 K | USA |
 |
Danaher Corporation
DHR
|
$ 233.86 | 4.32 % | $ 167 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.13 | -0.98 % | $ 620 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
IQVIA Holdings
IQV
|
$ 276.63 | 3.28 % | $ 47.6 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 323.75 | 0.19 % | $ 26.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.71 | 1.12 % | $ 88 K | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.24 | -0.15 % | $ 6.77 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 61.56 | 2.6 % | $ 2.88 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
$ 662.48 | 6.43 % | $ 19.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 677.94 | 2.69 % | $ 34.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 17.04 | 2.53 % | $ 2.18 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.79 | 0.6 % | $ 2.56 B | USA |
 |
National Research Corporation
NRC
|
$ 20.31 | -1.84 % | $ 455 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 11.98 | -0.42 % | $ 407 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.23 | 0.85 % | $ 24.9 B |  Niderland |
 |
Precipio
PRPO
|
$ 21.25 | -2.16 % | $ 34.1 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.37 | 3.68 % | $ 996 M | USA |
 |
Guardant Health
GH
|
$ 166.66 | 2.5 % | $ 20.9 B | USA |
 |
RadNet
RDNT
|
$ 68.41 | -1.78 % | $ 5.14 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 3.68 | -9.8 % | $ 14.7 M | Israel |
 |
DexCom
DXCM
|
$ 80.26 | -6.39 % | $ 31.3 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.97 | -2.92 % | $ 333 M | USA |
 |
Illumina
ILMN
|
$ 282.86 | 5.57 % | $ 43.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
VolitionRx Limited
VNRX
|
$ 0.17 | -2.63 % | $ 21.4 M |  Singapore |